The deal marks a departure for Shire, the UK's third biggest drug - maker, which is focused on therapeutic medicines such as its best - selling attention deficit hyperactivity disorder drug, Adderall XR.
He applied economic models to five years of sales data to estimate the price increases resulting from the delayed entry of a generic version of Adderall XR.